The study is based on a large and well described population of breast cancer patients and healthy controls and evaluates serum levels of both EGFR and EGFR ligands, enabling an extensive overview of blood levels of EGFR and EGFR ligands across the EGFR pathway in both healthy female controls and breast cancer patients. This evidence concerns the gene EGFR and breast carcinoma.